MentalHealthDaily

Approximately 13% of Psychiatrists with Major Depression in Thailand: Loneliness & Work Stress Factors (2024 Study)

by GLOOM

Depression, a pervasive mental health issue, affects individuals across various professions, including those within the psychiatric field. A recent study in Thailand sheds light on the prevalence and associated factors of Major Depressive Disorder (MDD) among psychiatrists and psychiatry trainees, offering insights into the mental well-being of those expected to be at the forefront of …

Symptom Provocation in Psychiatric Disorders: TMS, EEG, Neural Circuits for Personalized Treatment (2023 Review)

by GLOOM

Symptom provocation, a cornerstone of psychiatric research and therapy, offers a fascinating glimpse into the intricate relationship between brain activity and psychiatric symptoms. By deliberately triggering symptoms, researchers and clinicians can identify neurophysiological biomarkers and target them with personalized therapies, such as transcranial magnetic stimulation (TMS). This technique not only enhances our understanding of psychiatric …

Reset Modafinil Tolerance with Drug Holidays & Pitolisant-Bridging? (2023 Study)

by GLOOM

Narcolepsy, a chronic neurological disorder, significantly impacts the daily lives of those affected due to excessive daytime sleepiness (EDS). Modafinil has been a cornerstone in managing EDS, but its effectiveness can wane over time due to tolerance. An innovative approach, using the drug pitolisant during modafinil ‘drug holidays’, offers new hope for resetting tolerance and …

4 Depression Subtypes Identified via PHQ-9 Tool: Affective, Somatic, Internalizing, Sensorimotor (2023 Study)

by GLOOM

Depression, a multifaceted mental health disorder affecting millions worldwide, has long been a challenge for both diagnosis and treatment. The standard method for evaluating depression in outpatient settings, the Patient Health Questionnaire-9 (PHQ-9), has traditionally been viewed as a unidimensional tool. However, recent research suggests that the complexities of Major Depressive Disorder (MDD) may be …

Can Lifestyle Factors Modify Risk of Psychiatric Disorders? (2024 Study)

by GLOOM

Psychiatric disorders have increasingly become a significant public health concern, affecting a growing number of people globally. A study in focus utilized MR (Mendelian randomization), a method that leverages genetic data to explore causal relationships, to analyze the impact of 45 lifestyle factors on 13 psychiatric disorders. This extensive research involved GWAS summary statistics from …

Probiotics & Synbiotics for the Metabolic Side Effects of Psychiatric Medications: Are They Effective? (2024 Review)

by GLOOM

Patients with severe mental illnesses (SMI), such as schizophrenia and chronic depression, often face the challenge of managing weight gain and metabolic complications, side effects commonly associated with antipsychotics and antidepressants. These medications are known to induce increased appetite and weight gain, leading to long-term metabolic syndromes. Recent studies have evaluated into the role of …

Long-Term Buprenorphine Treatment: The Impact of Genetic & Psychiatric Factors (2024 Study)

by GLOOM

Opioid Use Disorder (OUD) remains a significant public health crisis, with buprenorphine emerging as a key medication in its treatment. Approved by the FDA, buprenorphine works as a partial opioid agonist, helping reduce opioid use and improve treatment retention rates compared to placebo. Despite its effectiveness, challenges in patient retention and optimal treatment duration persist. …